Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?

Gastric cancer (GC) remains a formidable global health challenge, ranking among the top-five causes of cancer-related deaths worldwide. The majority of patients face advanced stages at diagnosis, with a mere 6% five-year survival rate. First-line treatment for metastatic GC typically involves a fluo...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-02, Vol.16 (3), p.679
Main Authors: Mathias-Machado, Maria Cecília, de Jesus, Victor Hugo Fonseca, Jácome, Alexandre, Donadio, Mauro Daniel, Aruquipa, Marcelo Porfirio Sunagua, Fogacci, João, Cunha, Renato Guerino, da Silva, Leonard Medeiros, Peixoto, Renata D'Alpino
Format: Article
Language:English
Subjects:
Antibodies
Biomarkers
Cancer
Cancer therapies
Cell adhesion & migration
Chemotherapy
Clinical trials
Decision making
Drug therapy, Combination
Gastric cancer
Genotype & phenotype
Growth factors
Health aspects
Lymphatic system
Medical prognosis
Metastases
Metastasis
Oxaliplatin
Patients
Permeability
Proteins
Public health
Stomach cancer
Therapeutic targets
Tumors
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer (GC) remains a formidable global health challenge, ranking among the top-five causes of cancer-related deaths worldwide. The majority of patients face advanced stages at diagnosis, with a mere 6% five-year survival rate. First-line treatment for metastatic GC typically involves a fluoropyrimidine and platinum agent combination; yet, predictive molecular markers have proven elusive. This review navigates the evolving landscape of GC biomarkers, with a specific focus on Claudin 18.2 (CLDN18.2) as an emerging and promising target. Recent phase III trials have unveiled the efficacy of Zolbetuximab, a CLDN18.2-targeting antibody, in combination with oxaliplatin-based chemotherapy for CLDN18.2-positive metastatic GC. As this novel therapeutic avenue unfolds, understanding the nuanced decision making regarding the selection of anti-CLDN18.2 therapies over other targeted agents in metastatic GC becomes crucial. This manuscript reviews the evolving role of CLDN18.2 as a biomarker in GC and explores the current status of CLDN18.2-targeting agents in clinical development. The aim is to provide concise insights into the potential of CLDN18.2 as a therapeutic target and guide future clinical decisions in the management of metastatic GC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16030679